Emerging Issues in Cardiac Amyloidosis: Moving from rare and fatal, to a treatable chronic cardiovascular disease

Sunday, October 4, 2020 • 1:30 - 2:45 pm EDT

SYMPOSIUM AGENDA

1:30 PM  Welcome and Introduction
  •  Martha Grogan and Mathew Maurer

1:35 PM  Early Identification of Cardiac Amyloidosis and Monitoring Disease Progression
  •  Ahmad Masri

1:50 PM  Emerging Therapies for AL Cardiac Amyloidosis
  •  Ray Comenzo

2:05 PM  Neurologic Assessment for Early Diagnosis and Appropriate Therapy
  •  Sami Khella

2:20 PM  EP Issues in Cardiac Amyloidosis
  •  Wael Jaber

2:35 PM  Open audience Q&A with Panel
  •  All Faculty

2:45 PM  Adjourn

PROGRAM CO-CHAIRS

Martha Grogan, MD
Associate Professor of Medicine
Consultant, Division of Cardiovascular Diseases
Director, Cardiac Amyloid Clinic
Mayo Clinic
Rochester, MN

Mathew S. Maurer, MD
Professor of Medicine
Arnold and Arlene Goldstein Professor of Cardiology
Director, Clinical Cardiovascular Research Laboratory for the Elderly
Columbia University Medical Center / New York Presbyterian Hospital
New York, NY

FACULTY

Ahmad Masri, MD, MS
Co-Director, OHSU Amyloidosis Center
Assistant Professor of Medicine
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, OR

Raymond Comenzo, MD
Professor of Medicine
Tufts University School of Medicine
Attending Physician Division of Hematology-Oncology
Department of Medicine
Tufts Medical Center, Boston, MA

Sami Khella, MD
Professor and Chief of Neurology
Penn Presbyterian Medical Center
University of Pennsylvania
Philadelphia, PA

Wael A. Jaber, MD, FACC, FESC
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Fuad Jubran Endowed Chair in Cardiovascular Medicine
Heart and Vascular Institute
Cleveland Clinic, Cleveland, OH

LEARNING OBJECTIVES

Following this activity, participants will be able to:

• Define evaluation components necessary to improve early identification of cardiac amyloidosis.

• Review emerging therapies for AL cardiac amyloidosis including monitoring for disease progression.

• Describe common neurological symptoms and the role of the cardiologist in assessing for neurologic involvement.

• Identify indications and contraindications for antiarrhythmic therapies in amyloidosis patients with atrial fibrillation and other arrhythmias.

ACCREDITATION

Physicians:
Accreditation Statement: In support of improving patient care, The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. The Heart Failure Society of America designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses:
This educational activity is approved for continuing nursing education (CNE) units by the HFSA, an accredited provider of the American Nurses Credentialing Center. This activity is approved for a maximum of 1.25 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.

ELIGIBILITY

Registration for the HFSA Virtual Annual Scientific Meeting is required to attend this symposium.

Supported by independent medical education grants from Pfizer, Alnylam, and the Amyloidosis Research Consortium.

This satellite symposium is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.